Overview
The Brazilian regulatory landscape in 2026 solidifies the transition to a fully digital environment. With the mandatory implementation of Unique Device Identification (UDI) and new rules for electronic prescriptions, ANVISA focuses on patient safety and the de-bureaucratization of processes.
Introduction
The year 2026 marks a turning point for life sciences companies operating in Brazil. The Brazilian Health Regulatory Agency (ANVISA) has accelerated its international regulatory convergence schedule, implementing mechanisms that seek to balance sanitary rigor with the agility required for innovation.
In this post, we explore the key updates from March 2026, with a special focus on medical device traceability and the digitalization of surveillance workflows—fundamental pillars for compliance and competitiveness in the Brazilian market.
The New Era of Traceability: UDI and SIUD Implementation
The year 2026 marks a turning point for life sciences companies operating in Brazil. The Brazilian Health Regulatory Agency (ANVISA) has accelerated its international regulatory convergence schedule, implementing mechanisms that seek to balance sanitary rigor with the agility required for innovation.
In this post, we explore the key updates from March 2026, with a special focus on medical device traceability and the digitalization of surveillance workflows—fundamental pillars for compliance and competitiveness in the Brazilian market.
The New Era of Traceability: UDI and SIUD Implementation
On March 1, 2026, Normative Instruction No. 426 became the new standard for the Medical Devices sector. The implementation of the Unique Device Identification (UDI) system aims to create a “digital ID” for every health product circulating in the country.
The SIUD System: All companies must now populate the Medical Device Unique Identification System (SIUD) before commercialization.
Benefits: Higher precision in recalls, combatting counterfeit products, and effective monitoring of the product lifecycle.
Digitalization of Prescriptions and Legal Certainty
RDC No. 1.000/2025 reached full maturity in March 2026, bringing strict guidelines for the dispensing of controlled medications.
- End of “Photo Prescriptions”: The system now mandates qualified digital signatures (ICP-Brazil standard).
- Impact on Pharmacies: Integration between prescribers and dispensers via validated platforms reduces medication errors and fraud, raising the standard of pharmacovigilance in the country.
International Harmonization via VigiMed
In March, ANVISA reinforced the mandatory use of MedDRA (Medical Dictionary for Regulatory Activities) and WHODrug dictionaries for all adverse event reports. This standardization ensures that date generated in Brazil can be interpreted globally, facilitating the entry of Brazilian products into foreign markets and vice versa.
Conclusion
The regulatory agility proposed by ANVISA in 2026 does not mean less rigor, but rather smarter oversight tools. For companies, compliance has shifted from being a bureaucratic barrier to a strategic differentiator. Staying up-to-date with the SIUD and the new VigiMed notification standards is essential to ensure operational fluidity and, above all, the safety of the end patient.
GRP Brazil continues to closely monitor every update to ensure our partners remain ahead of market requirements.
GRP Brazil
If you are interested in registering your products in Brazil, GRP is ready to help. Our team of experts can simplify the process of registering products in Brazil and make it easier to schedule meetings with Anvisa more efficiently.
GRP can act as your local Agent & Register your product in U.S
Contact our team today to Inquire!
Email: info@globalregulatorypartners.com
Telephone : (+1) 781-672-4200
References
Learn more about Anvisa.
- National Health Surveillance Agency (ANVISA). Normative Instruction No. 426, 2024 (and 2026 updates). Establishes rules for SIUD. Brasília, DF.
- ANVISA. Collegiate Board Resolution – RDC No. 1,000/2025. Provisions on the control of electronic prescriptions.
- Adverse Event Notification Guide: Mandatory Use of MedDRA and WHODrug. March/2026 Version.
- Medical Device Single Audit Program – Regulatory Convergence Report 2026.
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.
GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea. GRP helps many life science companies register their products in different countries in compliance with local regulations.